Product Overview
Generic Peptides lists this material as Adipotide (FTPP) in two vials, 5 mg and 10 mg of freeze-dried powder. The catalogue name and the scientific name point at the same construct: a peptidomimetic whose sequence is written CKGGRAKDC-GG-D(KLAKLAK)2, an entity that has also travelled under the names prohibitin-TP01 and TP01. It is not a lipolytic peptide, and reading it as one is the first mistake a buyer can make.
The design is a two-part device. The first block binds annexin A2 and prohibitin on the endothelium of blood vessels that supply white adipose tissue, which in animal work gave the construct its selectivity for fat. The second block is the destructive half: once inside those endothelial cells it disturbs mitochondrial membranes and triggers apoptosis, so the vessel feeding a fat depot is removed and the adipocytes behind it lose their supply. Weight loss follows from a vascular event rather than from a signalling change in a fat cell, and that difference is precisely where the safety problem sits.
The record of testing is short and ends badly. In obese rhesus macaques dosed intravenously once a day for 28 days, the animals lost approximately 10.6 percent of body mass and needed about half the insulin they had required before, an outcome striking enough to draw attention. Dose-dependent changes in the kidney tubules appeared in the same study, and there was no clean gap between the effect and the damage. A phase I trial was announced in the early 2010s and produced no peer-reviewed results; as of 2019 clinical development of the compound is discontinued. Any reader looking for a fat-loss compound studied in humans should compare this vial with AOD 9604, which works on fat mobilisation instead of on its blood supply, and with the incretin route on Semaglutide and Tirzepatide. None of the three approaches is equivalent, and none was ever tested alongside the others.
Dosage Protocol
There is no human dose of this peptide, and the table is not a schedule. It sets out what the animal study used, what the vendor notes circulate as a convention, and the arithmetic that follows from a 5 mg or 10 mg fill.
| Animal reference | Daily intravenous dosing for 28 consecutive days in obese rhesus macaques, the only regimen in the sources |
| Vendor convention | Notes circulating in vendor material mention 500 mcg to 1 mg a day subcutaneously; no validated human protocol backs it |
| Dilution, 5 mg vial | 5 mg with 2 ml is 2.5 mg/ml; 5 mg with 1 ml is 5 mg/ml |
| Dilution, 10 mg vial | 10 mg with 4 ml is 2.5 mg/ml; 10 mg with 2 ml is 5 mg/ml |
| Unit arithmetic | At 2.5 mg/ml a 0.1 ml draw from a U-100 syringe holds 250 mcg; at 5 mg/ml the same draw holds 500 mcg |
| Stability | Powder cold and dark at 2-8 C; mixed solution 2-8 C for no more than 28-30 days, never frozen |
| Route | The primate work used the intravenous route; community notes describe subcutaneous use, which is a different exposure |
| Women | No data of any kind, since the compound has no human data in either sex |
Suggested Protocols
Combination research with this peptide does not exist, in animals or in people, so what follows is a shelf map. The reason to read the second card carefully is that the three approaches are often confused with one another purely because they are sold under the same fat-loss heading.
What to Expect
- Weight change in animals. Obese macaques lost about 10.6 percent of body mass across 28 days of daily intravenous dosing, which is the only efficacy figure in the sources.
- Insulin response. The same work reported improved insulin sensitivity, with roughly half the previous insulin amount needed.
- Mechanism. Fat cells are not signalled to release energy; the vessels feeding them are destroyed first, and the tissue then loses its supply.
- Kidney findings. Dose-dependent alterations in the kidney tubules appeared in the primate study, showing no separation between useful effect and organ damage.
- Empty human file. A phase I programme was announced but never published in a peer-reviewed journal, and development has been discontinued.
- No half-life, no dose. Human elimination was never measured and no human dose was set, so every figure quoted for this vial is either animal work or a vendor convention.
- Unknown long-term risk. A compound that ablates vessels in one tissue asks a selectivity question that the available data cannot answer.
Side Effects and Management
The concerns attached to this peptide are not cosmetic. They come from a single primate study and from the mechanism itself, and there is no human safety literature to soften or confirm any of them.
Post-Cycle Therapy
Hormonal recovery has no meaning for this vial, because it does not touch the axis that produces testosterone or estradiol and does not suppress fertility. Tamoxifen, clomiphene or hCG added to it would be treating nothing. What does deserve the slot that PCT normally occupies is monitoring, and the sources point in one direction only.
